Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 1 de 1
1.
Exp Neurol ; 350: 113929, 2022 04.
Article En | MEDLINE | ID: mdl-34813840

Obstructive sleep apnea-hypopnea syndrome (OSAHS) is widely known for its multiple systems damage, especially neurocognitive deficits in children. Since their discovery, adenosine A2A receptors (A2ARs) have been considered as key elements in signaling pathways mediating neurodegenerative diseases such as Huntington's and Alzheimer's, as well as cognitive function regulation. Herein, we investigated A2AR role in cognitive impairment induced by chronic intermittent hypoxia (CIH). Mice were exposed to CIH 7 h every day for 4 weeks, and intraperitoneally injected with A2AR agonist CGS21680 or A2AR antagonist SCH58261 half an hour before IH exposure daily. The 8-arm radial arm maze was utilized to assess spatial memory after CIH exposures.To validate findings using pharmacology, the impact of intermittent hypoxia was investigated in A2AR knockout mice. CIH-induced memory dysfunction was manifested by increased error rates in the radial arm maze test. The behavioral changes were associated with hippocampal pathology, neuronal apoptosis, and synaptic plasticity impairment. The stimulation of adenosine A2AR exacerbated memory impairment with more serious neuropathological damage, attenuated long-term potentiation (LTP), syntaxin down-regulation, and increased BDNF protein. Moreover, apoptosis-promoting protein cleaved caspase-3 was upregulated while anti-apoptotic protein Bcl-2 was downregulated. Consistent with these findings, A2AR inhibition with SCH58261 and A2AR deletion exhibited the opposite result. Overall, these findings suggest that A2AR plays a critical role in CIH-induced impairment of learning and memory by accelerating hippocampal neuronal apoptosis and reducing synaptic plasticity. Blockade of adenosine A2A receptor alleviates cognitive dysfunction after chronic exposure to intermittent hypoxia in mice.


Adenosine A2 Receptor Antagonists/therapeutic use , Cognition Disorders/prevention & control , Hypoxia, Brain/drug therapy , Hypoxia, Brain/psychology , Receptor, Adenosine A2A/drug effects , Animals , Brain-Derived Neurotrophic Factor/metabolism , Caspase 3/metabolism , Chronic Disease , Cognition Disorders/chemically induced , Cognitive Dysfunction , Hippocampus/pathology , Long-Term Potentiation/drug effects , Male , Maze Learning/drug effects , Mice , Mice, Inbred C57BL , Mice, Knockout , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Psychomotor Performance/drug effects , Pyrimidines/therapeutic use , Receptor, Adenosine A2A/genetics , Triazoles/therapeutic use
...